Biotie Therapies Oyj : Biotie's Annual Financial Report and Corporate
Governance Statement 2012 published
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 7 March 2013 at 9.00 a.m.
Biotie's Annual Financial Report and Corporate Governance Statement 2012
Biotie Therapies Corp.' s Annual financial report for the financial period
ended 31 December 2012 as well as Corporate Governance Statement 2012 have
The documents are attached in pdf format in this release. Both documents are
also available at Biotie's website www.biotie.com in English and Finnish
Turku, 7 March 2013
Biotie Therapies Corp.
President and CEO
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
NASDAQ OMX Helsinki Ltd
Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's
disease, Alzheimer's disease and other cognitive disorders, alcohol and drug
dependence (addiction) and post-traumatic stress disorder), and inflammatory
and fibrotic liver disease. The company has a strong and balanced development
portfolio with several innovative small molecule and biological drug
candidates at different stages of clinical development. Biotie's products
address diseases with high unmet medical need and significant market
Biotie's most advanced product, Selincro^TM (nalmefene), licensed to Lundbeck
A/S, has on 28 February 2013 received European marketing authorization for the
reduction of alcohol consumption in adult patients with alcohol dependence who
have a high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which is transitioning
into Phase 3 development,
Biotie shares are listed on NASDAQ OMX Helsinki Ltd.
Biotie_Financial statements 2012
Biotie_Corporate Governance Statement 2012
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Biotie Therapies Oyj via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.